{"id":4469,"date":"2026-03-31T00:39:24","date_gmt":"2026-03-31T00:39:24","guid":{"rendered":"https:\/\/inimmune.com\/?p=4469"},"modified":"2026-06-01T12:37:54","modified_gmt":"2026-06-01T12:37:54","slug":"inimmune-to-showcase-pipeline-advances-at-world-vaccine-congress-2026","status":"publish","type":"post","link":"https:\/\/inimmune.com\/?p=4469","title":{"rendered":"Inimmune to Showcase Pipeline Advances at World Vaccine Congress 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><em>Missoula, MT \u2014 March 29, 2026<\/em><\/strong> \u2014 Inimmune, a biotechnology company advancing next-generation vaccine adjuvants and immunotherapies, today announced that its leadership team will present new data and insights at the World Vaccine Congress (WVC) in Washington, DC, from March 30 to April 2, 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CEO David Burkhart, Ph.D., will chair the \u201cVaccine Technology Workshop\u201d on March 30 (Room 202, Level 2). That same day, Shannon Miller, Ph.D., VP of Operations, will present on the clinical development of a TLR4 agonist currently in Phase 2 trials for allergic rhinitis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chief Scientific Officer Jay Evans, Ph.D., will join the \u201cAdjuvants and Immunity\u201d panel on March 30 and moderate the April 2 session, \u201cGenetic Adjuvants &amp; mRNA Vaccine Durability: Next-Gen Strategies for Enhanced Immune Response.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Juhienah Khalaf, Ph.D., Director of Chemistry, will co-present with Peter Tygesen of SPI Pharma in the \u201cInnovative Adjuvants for Global Health\u201d session, highlighting collaborative efforts to develop affordable, accessible adjuvant systems and providing updates on Inimmune\u2019s expanding pipeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Across these sessions, Inimmune will showcase progress in its portfolio of immunomodulators and adjuvant platforms, underscoring its focus on enabling more precise, effective immune responses for vaccines and standalone therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cInimmune is proud to join global leaders at this year\u2019s World Vaccine Congress,\u201d said Dr. Burkhart. \u201cWe\u2019re excited to share advancements in\u00a0innate immune modulation,\u00a0adjuvant and delivery technologies that can help accelerate\u00a0immunological\u00a0innovation and enable new partnerships.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company recently completed a Phase 1a\/1b trial of INI-2004, a TLR4 agonist for allergic rhinitis, and has initiated a Phase 2 study in\u00a0January\u00a02026, with topline data reading out in June<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Missoula, MT \u2014 March 29, 2026 \u2014 Inimmune, a biotechnology company advancing next-generation vaccine adjuvants and immunotherapies, today announced that its leadership team will present new data and insights at the World Vaccine Congress (WVC) in Washington, DC, from March 30 to April 2, 2026. CEO David Burkhart, Ph.D., will chair the \u201cVaccine Technology Workshop\u201d [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"publication-year":[42],"class_list":["post-4469","post","type-post","status-publish","format-standard","hentry","category-press-releases","publication-year-42"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/inimmune.com\/index.php?rest_route=\/wp\/v2\/posts\/4469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inimmune.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inimmune.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inimmune.com\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/inimmune.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4469"}],"version-history":[{"count":0,"href":"https:\/\/inimmune.com\/index.php?rest_route=\/wp\/v2\/posts\/4469\/revisions"}],"wp:attachment":[{"href":"https:\/\/inimmune.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inimmune.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inimmune.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4469"},{"taxonomy":"publication-year","embeddable":true,"href":"https:\/\/inimmune.com\/index.php?rest_route=%2Fwp%2Fv2%2Fpublication-year&post=4469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}